Senate bill would bar “pay-for-delay” deals between brand-name and generic drug companies

We have blogged several times (here, here, here, here, and here) about the Federal Trade Commission's challenges to "pay-to-delay" settlements between brand-name and generic drug companies, in which the brand-name company pays the generic to delay selling a generic equivalent of the brand-name drug. The Legal Times reports that the new chair of the Senate's antitrust subcommittee has reintroduced today a bill to eliminate pay-off agreements to keep more affordable generic pharmaceuticals equivalents off the market.